Life UK Healthcare Limited (“LUHK”) is the UK holding company for a group of companies that operates in a number of countries including the UK. LUHK does not trade itself, the business in the UK is operated through its subsidiary companies Alliance Medical Limited (“AML”), Alliance Medical Radiopharmacy Limited (“AMRL”), Alliance Medical Leasing Limited (“AMLL”) and Alliance Diagnostic Services Limited (“ADSL”).
UK Business Overview
AML is a provider of complex diagnostic imaging services, and has provided those services for more than 30 years either through itself or its other trading subsidiary ADSL. AMRL manufactures and distributes radiopharmaceutical products which are used in conjunction with the diagnostic imaging services. AMLL purchases scanning equipment that is used by AML at certain sites to provide its diagnostic imaging services and is the principal contracting party for construction and development contracts for certain new sites. AML, AMRL, AMLL and ADSL, work collaboratively with clinicians, public and private healthcare organisations and academic institutions to provide high quality and cost effective diagnostic imaging services and radiopharmaceuticals to its customers and for its patients.
Its supply chains include procurement of scanning equipment and associated information technology equipment, transportation of mobile scanning units and radiopharmaceuticals, agency staff, medical and non-medical consumables, and construction and maintenance of buildings.
LUHK, AML, AMRL, AMLL and ADSL are committed to combating the real and growing problem of modern slavery and human trafficking.
We recognise that it can affect any sector or industry and we take seriously our responsibility to be alert to the risks, however small, in our business and in our wider supply chain.
We expect our people and our suppliers to share our commitment to ensuring modern slavery and human trafficking do not exist in our business or supply chains.
We operate employment policies and procedures that are designed to treat all individuals who work within our business with dignity and respect, to reward them fairly for their work and not to exploit them.
We only wish to work with organisations in our supply chains that have a similar commitment and are not involved in modern slavery.
While it is the obligation of those organisations to operate their own policies and procedures to achieve that objective, we will develop and build upon our existing practices to ensure we take all reasonable steps to verify compliance by all material direct suppliers with the Act.
Assessment of Risk within our Supply Chain
We have carried out a high level assessment of our supply chains and the potential for slavery and human trafficking. As the vast majority of our suppliers are based in the UK and many are operating in specialised rather than low skilled industries, our supply chains have been assessed overall as posing a low risk in terms of noncompliance with the Act .However, we will continue to periodically review and reassess this risk and are committed to procuring goods and services in a manner which recognises the importance of human rights, and we expect all of our suppliers to honour and observe the same principles.
Actions to be undertaken in the next 12 months
- To undertake a further more detailed risk assessment of material direct suppliers
- To include reference within the Groups Code of Conduct
- To obtain an annual assurance from material direct suppliers in relation to their compliance with the Act
- To introduce contractual clauses into our supplier contracts which require suppliers to provide appropriate undertakings to comply with the provisions of the Act and ensure that these are included in future supply contracts and contract renewals
- To continually review the provisions of the Act in relation to all business activities
Approval by Life UK Healthcare Limited’s, Alliance Medical Limited, Alliance Diagnostic Services Limited and Alliance Medical Radiopharmacy Limited’s Board of Directors
This statement for the financial year ending 30 September 2018 has been approved by each of the board of directors of Life UK Healthcare Limited, Alliance Medical Limited, Alliance Diagnostic Services Limited, Alliance Medical Leasing Limited and Alliance Medical Radiopharmacy Limited.
Mark Chapman – Chief Executive Officer – International